Chronic pain (pain persisting >3 months) affects 20% of US adults and represents one of the most common and economically costly conditions in medicine — with the opioid crisis having forced a fundamental reassessment of pain management paradigms. The evidence base for non-opioid chronic pain management has expanded significantly, with multiple modalities showing efficacy comparable to or greater than opioids for many chronic pain conditions, without the addiction, tolerance, and hyperalgesia risks of long-term opioid therapy.
Physical and Rehabilitative Interventions
Exercise therapy: the most universally evidence-supported non-pharmacological intervention for chronic pain across multiple conditions. Meta-analyses show exercise significantly reduces pain intensity in chronic low back pain (SMD −0.33), osteoarthritis (SMD −0.40), fibromyalgia (SMD −0.65), and chronic neck pain. Mechanism: exercise modulates central sensitization, improves endorphin signaling, reduces inflammatory cytokines, and improves functional capacity. Physical therapy (active rehabilitation vs. passive modalities): structured physical therapy with progressive exercise significantly outperforms passive modalities (TENS, ultrasound, massage) for long-term outcomes in chronic musculoskeletal pain. The emphasis on active patient participation is central to evidence-based PT for chronic pain. Cognitive Behavioral Therapy for pain (CBT-P): the most evidence-supported psychological intervention for chronic pain. CBT-P targets catastrophizing (the strongest psychological predictor of pain chronification), activity avoidance, and sleep disruption. Meta-analysis: CBT significantly reduces pain intensity (SMD −0.27) and disability (SMD −0.38) at follow-up, with effects maintained at 12 months.
Pharmacological Non-Opioid Options
SNRIs (duloxetine, venlafaxine): FDA-approved for diabetic peripheral neuropathy and fibromyalgia; evidence for chronic low back pain (Cochrane: modest but significant improvement in pain and function). Duloxetine NNT for 50% pain relief in fibromyalgia: 7. Pregabalin and gabapentin: first-line for neuropathic pain (diabetic neuropathy NNT 6, post-herpetic neuralgia NNT 8). Significant misuse potential (DEA scheduling for pregabalin under consideration). Topical agents: lidocaine 5% patch, diclofenac gel, and capsaicin 8% patch provide localized analgesia with minimal systemic effects — appropriate for localized neuropathic or musculoskeletal pain. Neuromodulation: spinal cord stimulation (SCS) for failed back surgery syndrome and complex regional pain syndrome — multiple RCTs showing 50%+ pain reduction in refractory cases. Transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS) show promising early evidence for fibromyalgia and headache. For clinical pain management facilities, our wound care catalog includes wound management supplies for procedure-based pain interventions, and our diagnostic equipment section supports comprehensive pain assessment.
